Our search failed to identify any current FDA-approved TBK1 inhibitors available on the market. The immunomodulatory drug Amlexanox which was approved by FDA for the treatment of aphthous ulcers in 2004 , was later discontinued in 2014 due to the associated undesired adverse reactions of the formulation. Amlexanox-loaded nanoliposome formulation are being currently developed as a potential alternative for the localized oromucosal delivery of the drug. The lack of FDA-approved TBK1 inhibitors at present can be attributed to several factors: (i) TBK1 is involved in multiple cellular processes, including immune regulation, inflammation, autophagy, and stress responses. The complexity of TBK1 signaling complicates the progress in TBK1 inhibitors. Developing inhibitors that selectively target TBK1's pathological functions while sparing its essential physiological roles is challenging.